[{"data":1,"prerenderedAt":159},["ShallowReactive",2],{"drug-prucalopride":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":42,"contraindications":65,"warnings":75,"renal":76,"monitoring":77,"interactions":78,"review":79,"examples":82,"atc":88,"iran":90,"usApproval":102,"links":108,"populations":124},"prucalopride",1,{"fa":7,"en":8},"پروکالوپراید","Prucalopride","alimentary-metabolism",{"fa":11,"en":12},"آگونیست گیرنده 5-HT4","5-HT4 receptor agonist",[14],{"name":15,"market":16},"Motegrity","US",[18,19,7],"motegrity","resolor",[21,34],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"tab-1","tablet","oral","1 mg tablet",{"amount":5,"unit":27,"perUnit":23,"scored":28},"mg",false,[16],[31],{"source":32,"section":33},"fda-motegrity","3",{"id":35,"form":23,"route":24,"label":36,"concentration":37,"markets":39,"refs":40},"tab-2","2 mg tablet",{"amount":38,"unit":27,"perUnit":23,"scored":28},2,[16],[41],{"source":32,"section":33},[43],{"id":44,"disease":45,"label":46,"population":49,"type":53,"unit":27,"dose":54,"refs":55,"notes":58},"cic","chronic-idiopathic-constipation",{"fa":47,"en":48},"یبوست مزمن ایدیوپاتیک — ۲ mg یک بار در روز","Chronic idiopathic constipation — 2 mg once daily",{"minAge":50},{"value":51,"unit":52},18,"year","fixed",{"perDose":38,"dosesPerDay":5},[56],{"source":32,"section":57},"2",[59],{"text":60,"refs":63},{"fa":61,"en":62},"CrCl زیر ۳۰: ۱ mg یک بار در روز.","CrCl \u003C30: 1 mg once daily.",[64],{"source":32,"section":57},[66],{"id":67,"severity":68,"text":69,"refs":72},"ci","block",{"fa":70,"en":71},"حساسیت؛ سوراخ یا انسداد روده، ایلئوس انسدادی، بیماری التهابی شدید روده (کرون، کولیت، مگاکولون توکسیک).","Hypersensitivity; intestinal perforation or obstruction, obstructive ileus, severe IBD (Crohn’s, colitis, toxic megacolon).",[73],{"source":32,"section":74},"4",[],[],[],[],{"status":80,"reviewer":81,"date":81},"unverified",null,[83],{"regimen":44,"formulation":35,"input":84,"expect":87},{"ageYears":85,"weightKg":86},45,65,{"perDose":38,"tabletsPerDoseRounded":5},[89],"A06AX05",{"status":91,"forms":92,"refs":97},"registered",[93],{"code":94,"en":95,"fa":96},"17328","PRUCALOPRIDE 2MG TAB","قرص پروکالوپراید ۲ میلی‌گرم",[98],{"source":99,"section":100,"url":101},"darooyab-generic","G-4792\u002FPrucalopride","https:\u002F\u002Fwww.darooyab.ir\u002FG-4792\u002FPrucalopride",{"kind":103,"refs":104,"id":107},"NDA",[105],{"source":32,"section":106},"SPL approval \u002F marketing category","NDA210166",[109,112,116,119,122],{"kind":110,"url":111,"label":107},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=210166",{"kind":113,"url":114,"label":115},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=bca1e4c6-4b2b-4876-8ab3-654629c4ff1b","FDA Motegrity",{"kind":117,"url":118,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa619011.html",{"kind":120,"url":121,"label":89},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A06AX05",{"kind":123,"url":101,"label":8},"darooyab",{"pregnancy":125,"lactation":134,"pediatric":142,"geriatric":150},{"level":126,"text":127,"quote":130,"refs":131},"caution",{"fa":128,"en":129},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data from case reports with prucalopride use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, major birth defects, or adverse maternal or fetal outcomes.",[132],{"source":32,"section":133},"8.1",{"level":126,"text":135,"quote":138,"refs":139},{"fa":136,"en":137},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Prucalopride is present in breast milk (see Data ) .",[140],{"source":32,"section":141},"8.2",{"level":126,"text":143,"quote":146,"refs":147},{"fa":144,"en":145},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of MOTEGRITY have not been established in pediatric patients.",[148],{"source":32,"section":149},"8.4",{"level":151,"text":152,"quote":155,"refs":156},"ok",{"fa":153,"en":154},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety and effectiveness were observed between elderly and younger patients.",[157],{"source":32,"section":158},"8.5",1792111466300]